A conditional agreement to acquire Pharmacure for 27.2 MSEK will expand the product portfolio, strengthen market position, and open new markets, with completion expected by Q3 2025 pending financing and regulatory approval.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.